Ferring wins FDA approval for label update to STIMATE nasal spray
Ferring Pharmaceuticals received FDA sign-off on a labeling supplement for its desmopressin acetate nasal spray STIMATE.
This week brought one regulatory update for Ferring Pharmaceuticals.
- Ferring Pharms Inc's STIMATE, a metered nasal spray formulation of desmopressin acetate delivered at 0.15mg per spray, received FDA approval for a labeling supplement dated July 15, 2026.1 The submission was classified as a standard-priority labeling change under supplement number 22 for NDA020355.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.